Elsevier

Journal of Psychiatric Research

Volume 28, Issue 4, July–August 1994, Pages 381-399
Journal of Psychiatric Research

Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment—Neurobiological and psychometric assessment of course

https://doi.org/10.1016/0022-3956(94)90020-5Get rights and content

Abstract

The present study was designed to investigate the clinical efficacy of trimipramine with adjunct sleep deprivation (SD) or bright light (BL) and to evaluate psychometric and neurobiological variables that might be of predictive value for treatment response. We used (1) the combined dexamethasone-corticotropin releasing hormone test (DEX-CRH test) to characterize alterations of the hypothalamic-pituitary-adrenal (HPA) system; (2) polysomnography to evaluate sleep disturbances; and (3) a standardized test battery to assess cognitive psychomotor functions after study initiation and after 5 weeks of treatment. The overall response rate (≥50% decrease in score on Hamilton Rating Scale for Depression [HRS] was 55% (N = 42). The response rate in the group with trimipramine monotherapy (N = 14) was 79%, whereas in the groups with adjunct SD (N = 14) and BL (N = 14), respectively, it was only 43%. All three groups showedsignificant improvement at the end of the third week of treatment. Neither of the adjunct treatments hastened the onset of antidepressant action as measured by HRS. A significantly higher proportion of nonresponders than responders (p<.05) had HPA dysregulation, disturbed rapid eye movement (REM) sleep (REM latency, REM% first third of night) and decreased non-REM sleep (% stage 2). The nonresponders showed significantly more corticotropin (ACTH) secretion after CRH stimulation in the DEX-CRH test than the responders and a less rapid normalization of the neuroendocrine dysregulation (cortisol secretion) (p<.01). In addition, REM latency was significantly shorter in the BL group than in the monotherapy group and estimated duration of illness significantly longer in the SD group than in the monotherapy group. REM latency, percentage of REM sleep during the first third of the total sleep period, percentage of non-REM sleep stage 2 and ACTH release after a DEX-CRH challenge predicted response across all three treatment groups. The neurobiological symptoms were unevenly distributed, among the three groups, thus creating heterogeneity in these measures. This heterogeneity may have contributed to the different treatment response rates as defined by psychopathology (HRS). In contrast, the neuropsychological tests and some of the sleep-EEG investigations revealed different response patterns for different groups: The onset of improvement is simple cognitive functions and in sleep continuity was earlier in the adjunct treatment groups. This study underlines the need for a multidimensional approach including use of neurobiological and neuropsychological measures to identify the therapeutic profiles of different treatment strategies and predictors of outcome.

References (58)

  • C. Lauer et al.

    Age, REM sleep, and depression

    Sleep Research

    (1992)
  • S.A. Montgomery et al.

    A new depression scale designed to be sensitive to changes

    British Journal of Psychiatry

    (1979)
  • C. Perris

    Bipolar-unipolar distinction

  • J. Schwitzer et al.

    Biologisch aktives Licht, ein Adjuvans in der Behandlung therapieresistenter endogener Depression

    Neuropsychiatrie

    (1990)
  • A. Steiger et al.

    Sleep-electroencephalography and the secretion of cortisol and growth hormone in normal controls

    Acta Endocrinologica (Copenhagen)

    (1987)
  • American Psychiatric Association

    Diagnostic and statistical manual of mental disorders

    (1987)
  • L.R. Baxter et al.

    Prolongation of antidepressant response to partial sleep deprivation by lithium

    Psychiatry Research

    (1986)
  • P. Bech et al.

    Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes

    Acta Psychiatrica Scandinavia

    (1986)
  • A.L.van Bemmel et al.

    Maintenance of therapeutic effects of total sleep deprivation by limitation of subsequent sleep

    Acta Psychiatrica Scandinavica

    (1981)
  • R. Brickenkamp

    Aufmerksamkeits-Belastungstest d2

    (1962)
  • D.P. Brunner et al.

    Repeated partial sleep deprivation progressively changes the EEG during sleep and wakefulness

    Sleep

    (1993)
  • C. De Montigny et al.

    Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression

    Archives of General Psychiatry

    (1983)
  • S. Elsenga et al.

    Sleep deprivation and clomipramine in endogenous depression

  • S. Elsenga et al.

    Clinical effect of sleep deprivation and clomipramine in endogenous depression

    Journal of Psychiatry

    (1982/1983)
  • M. Gastpar

    Clinical originality and new biology of trimipramine

    Drugs

    (1989)
  • A. Gerken et al.

    Weekly monitoring of dexamethasone suppression response in depression: its relationship to change of body weight and psychopathology

    Psychoneuroendocrinology

    (1985)
  • J.F. Greden et al.

    Dexamethasone suppression tests in antidepressant treatment of melancholia — the process of normalization and test-retest reproducibility

    Archives of General Psychiatry

    (1983)
  • M. Hamilton

    Development of a rating scale for primary depressive illness

    British Journal of Social Psychology

    (1967)
  • V. Hobi

    Apparative Test

  • Cited by (0)

    View full text